KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+2.74%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$169M
AUM Growth
+$169M
(-5.3%)
Cap. Flow
-$9.94M
Cap. Flow
% of AUM
-5.88%
Top 10 Holdings %
Top 10 Hldgs %
98.79%
Holding
13
New
–
Increased
2
Reduced
10
Closed
1
Top Buys
| 1 |
Enanta Pharmaceuticals
ENTA
|
$3.56M |
| 2 |
Indivior
INDV
|
$2.91M |
Top Sells
| 1 |
Exelixis
EXEL
|
$10.5M |
| 2 |
United Therapeutics
UTHR
|
$2.92M |
| 3 |
Biogen
BIIB
|
$700K |
| 4 |
BioNTech
BNTX
|
$561K |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$549K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $32.5M | 19.22% | 92,057 -8,275 | -8% | -$2.92M |
|
|
2
Exelixis
EXEL
$10.1B
| $32.2M | 19.03% | 965,866 -315,746 | -25% | -$10.5M |
|
3
Cardinal Health
CAH
$35.5B
| $24.7M | 14.61% | 208,845 -1,418 | -0.7% | -$168K |
|
|
4
Biogen
BIIB
$19.4B
| $16.7M | 9.85% | 108,923 -4,579 | -4% | -$700K |
|
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $13M | 7.71% | 105,803 -4,454 | -4% | -$549K |
|
|
6
Enanta Pharmaceuticals
ENTA
$180M
| $12.2M | 7.2% | 2,117,390 +619,316 | +41% | +$3.56M |
|
|
7
Indivior
INDV
$3.03B
| $11.6M | 6.88% | 935,680 +233,807 | +33% | +$2.91M |
|
|
8
BioNTech
BNTX
$24B
| $10.1M | 5.98% | 88,663 -4,920 | -5% | -$561K |
|
9
Sanofi
SNY
$121B
| $7.2M | 4.26% | 149,196 -1,009 | -0.7% | -$48.7K |
|
10
Alkermes
ALKS
$4.78B
| $6.85M | 4.05% | 238,136 -13,359 | -5% | -$384K |
|
11
Vanda Pharmaceuticals
VNDA
$279M
| $1.81M | 1.07% | 378,762 -35,922 | -9% | -$172K |
|
12
Mural Oncology
MURA
$35.7M
| $226K | 0.13% | 70,163 -5,705 | -8% | -$18.4K |
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| – | – | -353 | Closed | -$371K |
|